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An adenosine antagonist, 8-(3-chlorostyryl)caffeine (CSC), was shown previously to be 520-fold selective for A,,-adenosine receptors in radioligand 
binding assays in the rat brain. In reversing agonist effects on adenylate cyclase, CSC was 22-fold selective for Aza receptors in rat pheochromocy- 
toma cells (Kb 60 nM) vs. A, receptors in rat adipocytes (K,, 1.3 PM). Adrmnistered 1.p. in NIH mice at a dose of 1 mg/kg, CSC shifted the curve 
for locomotor depression elicited by the A,,-selective agonist APEC to the right (EDS, value for APEC shifted from 20 ,&kg i.p. to 190 @kg). 
CSC had no effect on locomotor depression elicited by an ED,, dose of the A,-selective agonist CHA. CSC alone at a dose of 5 mg/kg stimulated 
locomotor activity by 22% over control values. Coadmimstration of CSC and the A,-selective antagonist CPX, both at non-stimulatory doses, 
increased activity by 37% (P < 0.001) over CSC alone, suggesting a behavioral synergism of A,- and AZ-antagonist effects in the CNS. 
Adenosme receptor: Xanthine; Locomotor activity; Dopamine; Adenylate cyclase 
1. INTRODUCTION 
Adenosine agonists act as locomotor depressants 
through A, and AZ. receptor subtypes [l-3]. An in vivo 
synergistic relationship between activation of A, and 
A,, receptors in the brain was demonstrated using the 
selective agonists CHA (A,; N6-cyclohexyladenosine) 
and APEC (A,,; 2-[(2-aminoethylamino)carbonylethyl 
phenylethylamino]-5’-N-ethylcarboxamidoadenosine)[3]. 
The second messenger generally associated with ade- 
nosine receptors is cyclic AMP, the formation of which 
is inhibited by A, receptor activation and stimulated by 
A,, receptor activation [ 121. Ion channels and phospho- 
lipid turnover also can be modulated through A, recep- 
tors [4]. The stimulant effects of caffeine and other 
methylxanthines are related, at least in part, to their 
ability to block adenosine receptors [4], although the 
interpretation is complicated by action of these agents 
as phosphodiesterase inhibitors [4]. Furthermore, cer- 
tain potent and A,-selective adenosine antagonists, such 
as CPX (8-cyclopentyl-1,3_dipropylxanthine), do not 
stimulate locomotor activity [5]. 
Highly AZ-selective antagonists, various 1,3,7-trial- 
kyl-8-styrylxanthine derivatives, have only recently 
been synthesized [6]. We have explored the structure- 
activity relationships of 70 members of this class of 
compounds [7] and found that the highest selectivity in 
binding assays was obtained with 8-(3-chlorostyryl). 
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caffeine (CSC; 1,3,7-trimethyl-8-(3-chlorostyryl)xan- 
thine). CSC was 520-fold selective comparing affinity at 
A,, receptors in the rat striatum (K, 54 nM) and A, 
receptors in the rat cerebral cortex (K, 28 PM). In the 
present study it is shown that CSC also is highly selec- 
tive in functional adenylate cyclase assays and in vivo 
with respect to locomotor activity. 
2. EXPERIMENTAL 
2.1. Agents 
CSC and APEC were synthesized as described [7,8]. All other xan- 
thines and adenosine analogs are commercially avadable. 
2.2. Blorhemlcal actwit) 
Antagonism of NECA-elicited stimulation of adenylate cyclase via 
an AZd receptor in rat pheochromocytoma (PC12) cell membranes or 
in human platelets was assayed as described [lo]. Antagonism of 
A@-phenylisopropyladenosine-elicited inhIbition of adenylate cyclase 
via an A, receptor m rat adipocyte membranes was assayed as de- 
scribed [lo]. Kb values were calculated usmg the Schild equation from 
the ratio of EC,, values for agonist in the presence and absence of 
antagonist. 
2.3. Locomotor actwity 
Adult male mice of the NIH (Swiss) strain weighing 25-30 g were 
housed in groups of 10 animals per cage with a light-dark cycle of 
12:12 h. The animals were given free access to standard pellet food and 
water and were acclimatized to laboratory conditions for 24 h prior 
to testing. Each animal was used only once in the activity monitor. 
Locomotor activity of individual animals was studied in an open 
field using a Digiscan activity monitor (Omnitech Electronics Inc., 
Columbus, OH) eqmpped with an IBM-compatible computer. The 
computer-tabulated measurements represent multIvariate locomotor 
analysis with specific measures, such as simultaneous measurements 
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of ambulatory, rearing, stereotypical, and rotational behaviors Data 
was collected m the morning, for three consecutive Intervals of 10 min 
each, and analyzed separately and as a group. Statistical analysrs was 
performed using the Student’s r-test. The results are reported as 
mean + standard error for each point. All drugs were dissolved in a 
vehicle consisting of a 20:80 v/v mixture of Alkamuls EL-620 (Rhone- 
Poulenc, Cranbury, NJ) and phosphate-buffered sahne, except for 
CSC which was dtssolved initially in DMSO and diluted m at least 20 
~01s. of vehicle. Drugs were administered t.p. in a volume correspond- 
mg to 5 ml/kg body weight. Where apphcable. the antagonist was 
injected IO mm before the agonist. ED,,, values were determined using 
regression analysis on the InPlot software (GraphPAD, San Diego. 
CA). 
3. RESULTS 
In reversing adenosine agonist effects on adenylate 
cyclase (Table I), CSC was Z-fold selective for Aza 
receptors in rat pheochromocytoma (PCl2) cells vs. A, 
receptors in rat adipocytes. CSC displayed a lower po- 
tency in adenylate cyclase effects at A,, receptors in 
human platelets (Kb 260 nM) than at rat A:, receptors 
in PC12 cells (Kb 60 nM). This probably reflects the 
species difference: large differences in potency of xan- 
thines at A,,-adenosine receptors of different species 
have been noted previously [l 11. 
The locomotor effects in mice of CSC alone or in 
combination with the potent and AI,-selective agonist 
APEC [3] were examined. CSC administered i.p. at a 
maximum soluble dose of 1 mg/kg was found to nearly 
completely reverse the locomotor depression elicited by 
APEC at its previously determined [3] ED,, of 16 ,uglkg 
i.p. (Fig. 1A). A d ose of CSC of 5 mg/kg (injected as a 
suspension, since the solubility was exceeded at 1 mg/ml 
of injection vehicle) was found to cause significant loco- 
motor stimulation by 22% over vehicle control value. 
The total distance traveled in CSC animals was 
4,223 + 496 cm/30 min (n = 13) vs. 3,449 + 198 cm/30 
min (n = 8) in controls. This stimulation was most pro- 
nounced (56% increase vs. control) in the last 10 min of 
the 30 min monitoring period. Since CSC was not very 
efficacious in stimulating locomotor activity at the high- 
est tested dose, the ED,,, for CSC alone was not deter- 
mined. The concurrent administration of a 16 ,uglkg 
dose of APEC with 5 mg/kg CSC had no effect on the 
locomotor activity. The drug combination resulted in a 
total distance traveled of 3,949 + 284 cm/30 min 
(n = 14). This level of locomotor activity represents a 
73% increase vs. APEC alone with 2.277 ? 229 cm/30 
min (n = 13). 
CSC (5 mg/kg) had no effect on locomotor depression 
elicited by the potent A, agonist CHA at its determined 
ED,, value of 100 ,uglkg i.p. Coadministration of both 
drugs resulted in a total distance traveled of 2,029 _+ 250 
cm/30 min (n = 8) vs. 2.090 2 438 cm/30 min (n = 9) for 
the CHA control. 
Dose-response curves for locomotor depression by 
APEC in the absence and presence of CSC are presented 
in Fig. IB. The ED,, for locomotor depression elicited 
by APEC was right-shifted from 20 pug/kg i.p. to 190 
pg/kg following administratron of 1 mg/kg CSC. 
The A,-selective antagonist CPX was administered 
alone and in combination with CSC (Fig. 2). CPX alone 
resulted in a total distance traveled of 3,035 k 330 cm/ 
30 min (n = 14); i.e. a minimal depressant effect on loco- 
motor activity compared to control. CSC alone (1 mg/ 
kg) had no significant effect on locomotor activity. with 
a total distance traveled of 3,550 & 230 cm/30 min 
(11 = 19). However, the combination of the two antago- 
nists, each at a subthreshold dose, stimulated locomotor 
activity by 37% (P < 0.001) over CSC alone (total dis- 
tance traveled of 4,861 ? 243 cm/30 min, II = 9). sug- 
gesting a synergism of A,- and AZ-antagonist effects in 
the CNS. Following coadministration, the average dis- 
Table I 
Receptors affinities and effects of various xanthmes on adenosme agonist-elicited Inhibition (A,) or stimulation (A?) of adenylate cyclase 
Compd. Inhibition of bindmg (K,; ,uM) 
Rat cortex” Rat strtatumb 
A, AI, 
Adenylate cyclase (K,,; PM) 
Rat adipocytes Human platelets Rat PC 12 cells 
A, A,, A?, 
Behavtoral 
sttmulation” 
Caffeine 44 41 59 30 37 +++ (30) 
DMPX 45 16 94 4.0 96 +++ (10) 
CPT 0.024 14 nd. 0.14 n.d. ++d (10) 
CPX 0 0009 0.47 0.0006 0.14 0 25 - (I) 
csc 28 0.054 1.32 f 0 26 0.26 * 0.07 0.060 f 0.014 + (5) 
d vs. agornst ligand [‘HIP-phenylisopropyladenosine. 
‘vs. agomst hgand [‘H]N-ethylcarboxamidoadenosme. except vs. agonist ligand [‘H]CGS 21680 for CSC 
’ Degree of stimulation relative to vehicle control during a 30 mm momtoring period. Indicated by - (< 10%). + (lOK!5%), ++ (25~ 50%). and ++f 
(50150%). with a typical dose (mg/kg, 1.p.) shown in parentheses 
‘Stimulatory effect disappears withm 20 min post-mjectton [5]. 
nd. = not determmed. Values are means from prior pubhcations [7,9.10.12-141 or are means + S.E.M. (n = 34). 
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Fig. 1. (A) Locomotor activity in male NlH Swiss mice (6 week) by the A?-selective adenosme antagomst CSC alone (CJ) or in the presence of the 
AZ-selective agonist APEC at 16 ,ug/kg (01. (B) Locomotor depression in mice by APEC alone (0) or in the presence of CSC at 1.0 mg/kg (A). 
n = 6-19. *P =z 0.005; **P < 0.01; ***p < 0.025 
tance per move was increased by approximately 30%, 
and clockwise and anti-clockwise rotations were in- 
creased in the range of 30-60% (data not shown). 
4. DISCUSSION 
An A2 antagonist suitable for in vivo use has been 
lacking. Previously, a low affinity antagonist 3,7-di- 
methyl-1-propargylxanthine (DMPX) was reported to 
be A2 selective, by less than one order of magnitude [ 131. 
It was relatively weak in blocking the in vivo effects of 
CHA compared to those of NECA, suggesting some A, 
selectivity. Several non-xanthine antagonists of the 
triazoloquinazoline class, including CGS 15943, are A,- 
selective but also by only one order of magnitude [16]. 
The locomotor activity of several members of this class 
was described previously [17]. A triazoloquinoxaline de- 
rivative, CP66.713. was found to be 12-fold selective in 
binding assays at rat brain A,, vs. A, receptors [18]. 
Low selectivity, interspecies differences in affinity, and 
low water solubility precluded extensive use of this com- 
pound. In one study, partial antagonism of A2 depres- 
sion of locomotor activity was achieved in vivo using 
CP66,713 [3]. At the same dose CP66,713 had no effect 
on A, depression of locomotor activity. 
The 8-styrylxanthine derivatives reported by 
Shimada et al. [6] appear to be among the most A,- 
selective antagonists currently known. A further struc- 
ture-activity study [7] introduced CSC as a particularly 
AZ-selective member of that class of xanthines. Since at 
the highest dose administered there was essentially no 
effect on the locomotor depression elicited by CHA, 
CSC is a functionally specific antagonist at Aza vs. A, 
receptors in mice in vivo. In future studies with CSC it 
will be useful to determine the blood and brain concen- 
trations of the drug and effect on cardiovascular func- 
tion [6]. The selectivity of CSC for A,, vs. A,, (low 
affinity for agonists) receptors is yet to be established. 
It should be noted however that a physiological role has 
not yet been assigned to the low affinity A,, receptor. 
A relationship between the striatal dopaminergic and 
the adenosine A, systems has been proposed (reviewed 
in [ 191). Activation of A?, receptors inhibits a dopamin- 
ergic pathway in the striatum. D,-dopamine receptors 
and A,, receptors are colocalized on the subset of 
GABAergic neurons in the striatum innervating the 
globus pallidus and expressing enkephalin. Thus. an A, 
antagonist would be expected to enhance dopaminergic 
striatopallidal transmission. The other class of striatal 
GABAergic neurons, those expressing substance P, are 
located in the striatonigral pathway. An A, antagonist 
would not have a direct postsynaptic action on striato- 
pallidal neurons, but might still affect both striatopalli- 
da1 and striatonigral dopaminergic pathways by en- 
hancing the release of dopamine in the striatum. Activa- 
tion of presynaptic A, receptors is associated with the 
inhibition of release of stimulatory neurotransmitters in 
the CNS [19]. 
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Fig. 2. Synergism of an A,-selective antagonist (CPX. 0.15 mg/kg. i.p ) 
and an AZ-selective antagonist (CSC. 1.0 mg/kg. 1.p ) in shmulating 
locomotor activity m mice. I* = 9-19. *P < 0.001 vs. CSC alone. 
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Selective A, and A,, antagonists alone are either non- 
stimulatory or weakly stimulatory in locomotor activity 
(Table I), but the combination (as we have shown for 
subthreshold doses of CSC and CPX) causes substantial 
stimulation (Fig. 2). An increase in rotational move- 
ment, seen with the combination of A, and A,, antago- 
nists, is also observed with maximal stimulant doses of 
caffeine (unpublished results). This suggests the possi- 
bility that enhancement of dopaminergic action by 
blocking both presynaptic (A,) and postsynaptic (A,,) 
mechanisms might be required for substantial locomo- 
tor stimulation by xanthines. The pronounced enhance- 
ment of locomotor activity by non-selective xanthines 
(Table I) such as caffeine and theophylline [1,3] is con- 
sistent with this view. The moderate, but transient loco- 
motor stimulation by CPT (8-cyclopentyltheophylline) 
may result from its non-selectivity in vivo at high doses 
(Table 1). The synergistic behavioral depressant effects 
of A, agonists in combination with A,, agonists [3] is 
also consonant with this proposal. 
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